Examining 192 ads in 12 journals, researchers found that 58 percent didn’t calculate serious risks of the drugs, including death, while 48 percent didn’t have references that could be confirmed and almost 29 percent couldn’t adequately quantify effectiveness.
Researchers recommended the FDA create more objective advertisement guidelines requiring transparent presentation of basic safety and efficacy information.
Related Articles on Pharmaceuticals:
Amerinet, Sandoz Sign Agreement for Pharmaceutical Products
6 Things to Know About Pharmaceuticals and Outsourcing Pharmaceutical Solutions
Pfizer Reports “Potentially Improper Payments” Made Outside U.S.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
